Ratings Divi's Laboratories Limited

Equities

Market Closed - NSE India S.E. Other stock markets 05:19:41 11/07/2025 pm IST			5-day change	1st Jan Change
6,835.00 ^INR	-0.14%		-0.60%	+12.07%

08/07	Divi's Laboratories Limited, Q4 2025 Earnings Call, May 17, 2025
08/07	INDIA STOCKS-India's stock benchmarks muted on tariff jitters; Trump says India deal close	RE

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

The prospective high growth for the next fiscal years is among the main assets of the company
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

With an expected P/E ratio at 85.08 and 67.31 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	DIVI'S LABORATORIES LIMITED				2.12TCr
	ELI LILLY AND COMPANY				71TCr
	JOHNSON & JOHNSON				38TCr
	ABBVIE INC.				34TCr
	NOVO NORDISK A/S				32TCr
	ROCHE HOLDING AG				26TCr
	NOVARTIS AG				24TCr
	ASTRAZENECA PLC				22TCr
	MERCK & CO., INC.				21TCr
	AMGEN INC.				16TCr
	Average				28.76TCr
	Weighted average by Cap.